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Abstract The tumor necrosis factor receptor-associated
factors (TRAFs) have been classically described as adap-
tor proteins that function as solely cytosolic signaling in-
termediates for the TNF receptor superfamily, Toll-like
receptors (TLRs), NOD, like receptors (NLRs), cytokine
receptors, and others. In this study, we show for the first
time that TRAFs are present within the cytoplasm and
nucleus of Neuro2a cells and primary cortical neurons,
and that TRAF2 and TRAF3 translocate into the nucleus
within minutes of CD40L stimulation. Analysis of the
transcriptional regulatory potential of TRAFs by lucifer-
ase assay revealed that each of the TRAFs differentially
functions as a transcriptional activator or repressor in a
cell-specific manner. Interestingly, ChIP-qPCR data dem-
onstrate that TRAFs 2/3, p65, and pRNAPol II form part
of a transcriptional complex on the Icam-1 gene promoter
upon CD40L stimulation. We further determined that
TRAF2 recruitment to the nucleus is critical for the
ubiquitination of H2b, a transcription permissive epige-
netic modification. Our findings demonstrate for the first
time that TRAFs 2/3 participate in the formation of a
CD40L-induced transcriptional complex in neuronal
cells.
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Introduction
The tumor necrosis factor receptor-associated factors
(TRAFs) have been classically described as cytosolic
adaptor proteins that function as signaling intermediates
for different receptor families, such as the TNF receptor
superfamily, Toll-like receptors (TLRs), NOD, like receptors
(NLRs), cytokine receptors, and others. TRAFs are thought to
facilitate interactions between kinases and other signaling
platforms and corresponding upstream receptors. Since the
receptors that the TRAFs interact with lack catalytic activity
of their own, activation of downstream signaling pathways
has been hypothesized to be orchestrated predominantly by
TRAF proteins, although the exact mechanisms by which
the TRAFs regulate such activity remain to be elucidated
([1, 2] and references therein ).
There are currently seven known members of the TRAF
protein family. Of these, TRAFs 1–6were identified based upon
the presence of a conserved C-terminal TRAF domain, which
has been found to mediate the homo-/hetero-oligomerization
of the TRAFs with one another, as well as interactions
with the various upstream regulators and downstream effec-
tors [3–8]. TRAFs 1–6 also contain a variable number of
TRAF zinc-finger domains, and, with the exception of
TRAF1, a RING finger domain [1] The RING finger domain
is common to many E3 ubiquitin ligases, and in fact, TRAFs
2, 3, 5, and 6 have been reported to possess E3 ubiquitin ligase
activity [2, 9–11]. TRAF7 was more recently identified to be a
TRAF protein based upon the similarity of its RING- and
zinc-finger domains to those of the TRAFs; however, it lacks
the C-terminal TRAF domain [12].
While most recent studies describe TRAFs as cytosolic
adaptor proteins with E3 ubiquitin ligase activity earlier stud-
ies compared TRAFs 1–3 to the STAT protein family, due to
their sequence homology and the presence of both RING- and
zinc-finger domains, which are traditionally considered to be
DNA-binding domains [13–17]. In support of this possibility,
there are several examples in which TRAFs have been found
within the nucleus [18–20] and other instances where overex-
pression of either the full-length or domain-deletion isoforms
explicitly altered the subcellular localization of TRAFs
[20–22]. Furthermore, while nuclear localization sequences
(NLSs) have not been identified for the TRAFs, TRAF3 has
been found to interact directly with p62 nucleoporin, which
binds to classical NLS-containing import complexes during
activity-dependent nuclear translocation [23].
In our preliminary studies, we analyzed the intracellular
activation of components of the nuclear factor-kappa B
(NF-kB) signaling pathways downstream of the CD40 receptor
in mouse cortical neurons and Neuro2a cells. We focused our
studies on the CD40 receptor for two reasons: first, it is among
the few receptors that are known to activate both the classical
and the alternative NF-kB pathways. Second, it has been
shown to interact with the majority of the TRAF proteins:
TRAFs 1, 2, 3, 5, and 6 [5, 7, 8, 23, 24]. In addition, the
CD40 receptor has been shown to be both present and func-
tional in primary neurons [25]. Our preliminary data demon-
strated the presence of TRAFs within the nucleus. Therefore,
we hypothesized that the TRAFs may have a nuclear function
and decided to investigate further.
In this study, we show that each of the TRAFs are present
within the nucleus of Neuro2a cells, and that TRAFs 2 and 3
translocate into the nucleus of Neuro2a cells following 5 to
10 min of CD40L stimulation. We also show that TRAF2
translocates into the nucleus of primary cortical neurons,
while TRAF3 is constitutively present within the nucleus at
relatively high levels. Once in the nucleus, these proteins in-
teract with chromatin and are able to bind to the NF-kB con-
sensus element. Furthermore, both TRAFs 2 and 3 appear to
be essential components of the NF-kB DNA-binding com-
plexes, and each of the TRAFs 1–7 can function as a tran-
scriptional regulator, either as a coactivator or corepressor.
Additionally, we found that TRAF2 can function directly as
a transcription factor and that its transcriptional regulatory
potential depends upon the presence of an intact RING finger
domain. Within the nucleus, TRAF2 and TRAF3 bind to the
Icam-1 gene promoter in a complex containing p65 and
pRNAPol II. We further show that a complex containing
TRAF2 ubiquinitates H2b. This is the first demonstration that
TRAFs function within the nucleus to regulate transcription
and epigenetic modification of histones.
Experimental Procedures
Cell CultureNeuro2a cells were cultured at 37 °C in 1:1 Opti-
minimum essential medium (MEM)/Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 5 % fetal bo-
vine serum (FBS), 100 IU/mL penicillin/streptomycin (P/S),
and 2 mM L-glutamine (L-glut) (Gibco) [19]. Daudi cells were
cultured at 37 °C in RPMI 1640 (Gibco) supplemented
with 10 % FBS, 100 IU/mL P/S, 2 mM L-glut, 55 μM
2-mercaptoethanol (Fisher Biotech) , 20 μg/mL gentamycin,
and 1 mM Na-pyruvate (Gibco) according to the American
Type Culture Collection protocol. HEK 293 cells were cul-
tured at 37 °C in DMEM supplemented with 10 % FBS and
100 IU/mL P/S [20]. Primary cortical neurons were prepared
from the cortices of E15 C57BL6 mouse embryos. The cells
were cultured at 37°C in Eagle’s basal medium (BME)
(Gibco), supplemented with 10 % FBS, 100 IU/mL
P/S, 2 mM L-glut, 25 mM KCl, and 10 μM cytosine
β-D-arabinofuranoside (Sigma) [21].
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Expression Vectors and Transfections The Gal4-TRAF and
RelA fusion protein constructs were generated by cloning the
individual TRAF and RelA cDNAs into the pBind vector
(Promega). The TRAF constructs that were used for
cotransfection with Gal4-tagged RelA were developed by
cloning the individual TRAF cDNAs into the pCMV-Tag2B
vector (Stratagene). Each of the cDNAs were amplified from
the whole genome cDNA library (Promega) by polymerase
chain reaction and sequenced. The TRAF2 N-terminal
RING-finger deletion (ΔN-TRAF2) constructs were generat-
ed by removing a 261-bp DNA fragment corresponding to the
N-terminal 87 amino acids of TRAF2 [22]. Cells were
transfected using Lipofectamine 2000, according to the man-
ufacturer’s instructions (Invitrogen).
Protein ExtractionWhole cell extracts were prepared by lys-
ing the cells in radioimmuno-precipitation assay buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 % NP-40,
0.5 % sodium deoxycholate, 1 mM EDTA, 1 mM
phenylmethyl-sulfonyl fluoride, 1 mM dithiothreitol (DTT),
1× complete protease inhibitor (Roche), and 1× phosphatase
inhibitor cocktail I and II (Sigma)) [23]. To prepare cytoplas-
mic and nuclear extracts, the cells were first incubated for
30 min with buffer A (10 mM HEPES, pH 7.9; 1.5 mM
MgCl2; 10 mM KCl; 0.5 mM DTT; 1× complete protease
inhibitor; 1× phosphatase inhibitor cocktail I and II; 0.8 %
NP-40) and centrifuged at 4600×g for 10 min. Following cen-
trifugation, the cytoplasmic extracts were collected, and the
isolated nuclei pellets were washed three times with
phosphate-buffered saline (PBS), and then incubated for
30 min with buffer B (50 mM HEPES, pH 7.9; 0.4 M KCl;
0.75 mM MgCl2; 0.5 mM EDTA; 12.5 % glycerol; 0.5 mM
DTT; 1× complete; 1× phosphatase inhibitor cocktail I and II).
After 30 min, the samples were centrifuged at 18,300×g for
10 min, and the nuclear extracts were collected [21, 24]. All
steps were carried out at 4 °C.
Chromatin Binding Assays For chromatin binding assays,
the residual chromatin pellets following soluble nuclear pro-
tein extractions were washed with PBS, and then incubated in
buffer B supplemented with deoxyribonuclease I (Sigma) for
2 h on ice. After 2 h, an equivalent volume of 2× high salt
solution (300 mMNaCl; 2 % Triton X-100; 100 mMHEPES,
pH 7.5; 20 % glycerol; 1× complete; 1× phosphatase inhibitor
cocktail 1 and II) was added to the samples, followed by an
additional hour incubation on ice. The samples were then
centrifuged at 18,300×g for 15 min, and the chromatin ex-
tracts were collected [25]. All steps were carried out at 4 °C.
Western Blotting Protein extracts were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, trans-
ferred to nitrocellulose membranes, and the membranes
were blocked for 1 h in Tris-buffered saline-0.1 % Tween 20
(TBS-t) containing 5 % bovine serum albumin (BSA).
Following overnight incubation with the primary antibodies in
blocking solution at 4 °C, the membranes were washed three
times and then probed with HRP-conjugated secondary antibod-
ies for 1 h at room temperature (RT). The antibodies were visu-
alized using an enhanced chemiluminescence kit (ECL; GE
Healthcare). The primary antibodies that were used were
anti-TRAF1 (sc-1831), anti-TRAF2 (sc-876), anti-TRAF3
(sc-949), anti-TRAF4 (sc-1921), anti-TRAF5 (sc-52967),
anti-TRAF6 (sc-7221), anti-TRAF7 (sc-49545), anti-glucose
transporter 3 (Glut3) (sc-30107), anti-heat shock protein 60
(HSP60) (sc-13115), anti-RNA polymerase II (RNA pol II)
(sc-899) (Santa Cruz Biotechnologies), anti-RelA (#3036),
anti-Lamin A/C (#2032), anti-histone deacetylase
1 (HDAC1) (#2062) (Cell Signaling Technologies),
anti-histone H3 (#07-690) (Upstate Signaling Solutions), and
anti-β-actin (A5441) (Sigma). After probing, the membranes
were stripped in stripping buffer (62.5 mMTris, pH 6.8; 0.4 %
SDS; 100 mM 2-mercaptoethanol) for 40 min at 65 °C,
washed in TBS-t, and then reblocked. As controls for both
the loading and the relative purity of the cytoplasmic and
nuclear extracts, Glut3 (26) and HSP60 (27) were used as
cytoplasmic markers, while HDAC1 (28), Lamin A/C (29),
and RNA Pol II were used as nuclear markers. Furthermore,
additional validation, via blocking peptide, of the TRAF2 and
TRAF antibodies was performed to ensure specificity as they
were used also in the ChIP experiments (Supplemental Fig. 2).
Electrophoret ic Mobil i ty Shift Assay (EMSA)
Oligonucleotide consensus sequences (Santa Cruz; Promega)
were 32P-labeled with T4 polynucleotide kinase (Promega).
Equal amounts of nuclear extracts were either untreated or
preincubated with 200 ng of antibody to TRAF2 or TRAF3,
or with 100-fold excess of unlabeled NF-kB or NFATconsen-
sus elements. The samples were then incubated with the
radiolabeled consensus sequence for 30 min at RT in
DNA-binding buffer (10 mM Tris, pH 7.5; 50 mM NaCl;
1 mM MgCl2; 0.5 mM EDTA; 0.5 mM DTT; 4 % glycerol)
supplemented with 125 μg/mL poly(dI-dC):poly(dI-dC)
(Sigma). After 30 min, the samples were loaded onto a pre-
electrophoresed 6 % polyacrylamide gel in 0.5× Tris-borate
EDTA buffer, and separated at 150 V for ∼1.5 h. Gels were
then fixed and dried, and autoradiograms were obtained.
NF-kB Consensus Oligo Precipitation Assay NF-kB con-
sensus oligo-coated agarose beads were obtained from Santa
Cruz Biotechnologies. Nuclear extracts were incubated with
the beads overnight in DNA-binding buffer [20]. The follow-
ing day, the beads were centrifuged at 12,000×g for 10 min at
4 °C. The samples were then washed three times with
DNA-binding buffer and then incubated at 100 °C for 5 min
in 2× SDS sample buffer (125mMTris–HCl, pH 6.8; 4%SDS;
20 % glycerol; 0.2 M DTT; 0.02 mg/mL bromophenol blue).
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Finally, Western blots were performed on the fractionated
samples, according to the protocol described above.
Gal4 Luciferase Assays The Gal4-TRAF and RelA fusion
protein constructs were cotransfected into Neuro2a and
HEK 293 cells along with either the 4x Gal4-minimal thy-
midine kinase (TK) promoter-driven luciferase plasmid (R.
Evans, Salk Institute), the 5x Gal4 promoter-driven luciferase
plasmid (Promega), or the NF-kB promoter-driven luciferase
plasmid (Clontech). The Gal4-RelA fusion protein constructs
were additionally transfected either with or without the
flag-tagged TRAF protein constructs. At 24 h posttransfection,
lysates were collected and luciferase assays were performed
according to the Promega Dual-Luciferase Reporter Assay
System Technical Manual (Promega).
siRNA Transfection TRAF2 siRNAs were procured from
Dharmacon (Chicago, IL) as ON-TARGET plus SmartPools.
Nontargeting siRNAs (siScr) were used as negative controls.
siRNAs were reverse transfected into Neuro2a cells using
Lipofectamine RNAimax (Invitrogen) as per the manufac-
turer’s protocol. Briefly, 50 nM siRNA was diluted in
0.5 mL of OPTIMEM reduced serum medium (Invitrogen)
along with 5 μl of Lipofectamine RNAimax on each well of
a six-well plate. Cells (1 × 105) in 8 mL of antibiotic-free
media were added to the transfection mixture. Twenty-four
hours later, the media was replaced with media with antibi-
otics. Efficiency of knockdown was assessed via quantitative
PCR (Supplemental Fig. 3 B and C)
Chromatin Immunoprecipitation (ChIP) Neuro2a cells
were fixed with 1 % formaldehyde (in PBS) for 10 min,
washed in ice-cold PBS for 5 min, and then quenched with
glycine stop buffer (125 mM glycine in PBS) for 5 min. Cells
were subsequently washed in ice-cold PBS for 5 min. Cells
were then scraped in PBS containing phenylmethylsulfonyl
fluoride (PMSF), spun, and resuspended in lysis buffer
(50 mM HEPES pH 8.0, 1 mM EDTA, 140 mM NaCl,
10 % glycerol, 0.5 % NP-40, and 0.25 % Triton X-100) to
sit on ice for 30 min. Lysate was then homogenized with a
type-B Dounce homogenizer using 15 strokes per sample.
Nuclear fraction was then collected by pelleting and resus-
pended in 600 μL of sonication buffer (10 mM Tris pH 8.0,
1 mM EDTA, 140 mM NaCl, 1 % SDS, 0.1 % sodium
deoxycholate, and 1 % Triton X-100). Cells were then soni-
cated using a Misonix S-4000 sonicator for 10 s at 20 % pow-
er. Ten microliters of the sheared DNAwas aliquoted out and
considered input DNA. For ChIP, 100 μL of sheared DNA
was diluted 10-fold in buffer Y (16.7 mM Tris pH 8.1,
167 mM NaCl, 0.01 % SDS, 1.1 % Triton X-100, and
1.2 mM EDTA). Diluted sheared DNA was precleared with
2 μg of appropriate IgG antibody and salmon sperm-coated
DNA agarose beads (Millipore) for 1 h at 4 °C. Beads were
spun at 0.6 rcf for 1 min, and supernatant was moved to a fresh
tube. Two micrograms of specific antibody was then used for
overnight IP at 4 °C. Salmon sperm-coated DNA agarose
beads were then added for 1.5-h incubation. Beads were spun
at 0.6 rcf for 1 min. Beads were washed once in TSEI (0.1 %
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.1,
150 mMNaCl), once in TSEII (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris pH 8.1, 500 mM NaCl), once in
TSEIII (0.5 M LiCl, 1 % NP-40, 1 % sodium deoxycholate,
1 mM EDTA, 10 mM Tris pH 8.1, 150 mM NaCl) and then
two times in TE (1 mM EDTA, 10 mM Tris pH 8.1) for 5 min
each. DNA was then eluted twice using elution buffer (1 %
SDS and 0.1 M NaHCO3) for 15 min each elution, 75 μL of
buffer each time. Ten microliters of input DNA was diluted
1:10 with buffer Y. One hundred fifty microliter elutions and
input DNAwere then reverse cross-linked by addingNaCl to a
final concentration 200 mM and incubating for 5 h or over-
night at 65 °C. Proteins were removed by bringing elutions to
a final concentration of 10 mMEDTA and 40mMTris pH 6.8
with 1.25 units of proteinase K for 1.5 h at 45 °C. DNA
from elutions was then purified using a Qiagen pcr purifi-
cation kit. DNA was used directly in qPCR reactions.
Antibodies used were pRNA pol II (Abcam), H2Bub
(clone 56, Millipore), TRAF2 (Santa-Cruz), TRAF3
(Santa Cruz), and p65 (Santa Cruz).
Quantitative RT-PCR RNA was isolated using the Qiagen
RNAeasy kit as per the supplier’s protocol. cDNA synthesis
(iScript cDNA Synthesis kit) and real-time PCR analysis (iQ
SYBR Green Supermix) were performed using the protocol
provided with the products (Bio-Rad, Hercules, CA). Then,
DNAwas quantified by real-time quantitative PCR using spe-
cific primers (for Icam-1: forward, 5′-CATCTCCTAAGATG
ACCTGC-3′, reverse, 5′-GTACACATTCCTGGTGACAT-3′;
for TRAF2: forward, 5′-AGGCCAAGAATTCCTATGTG-3′,
reverse, 5′-CTCACTGAGCTGCTATTCTT-3′; for p65: for-
ward, 5′-CAGACCCAGGAGTGTTCACAGA-3′, reverse,
5′-ACATGGACACACCCTGGTTCA-3′; for Gapdh (used
as control): forward, 5′-GGGTGTGAACCACGAGAAAT-
3′, reverse, 5′-CCTTCCACAATGCCAAAGTT-3′). On the
other hand, ChIP DNAwas quantified by real-time quantita-
tive PCR using Icam-1 promoter-specific primers (for p65
consensus/TSS: forward, 5′-CATTACTTCAGTTTGGAAA
TTCCTAGATC-3′, reverse, 5′-GGAACGAGGGCTTCGGT
ATT-3′; for Ctrl: forward, 5′-GCCTGTGAGTGTGCT
CTCTG-3′, reverse, 5′-ACGACCTGAGAAGGGACCTG-
3′). To note that the p65 consensus/TSS primers cover a
150-bp promoter sequence that includes the p65 consensus
sequence and the transcriptional start site (TSS) of the Icam-
1 gene. Real-time PCR were performed using the Roche
Lightcycler II real-time PCR detection system (Roche). To
avoid variations from different samples, the relative Icam-1
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mRNA levels were normalized against GAPDH mRNA con-
tent of the same sample.
Immunofluorescence and Confocal Microscopy
Subconfluent Neuro2a cells grow on cover slips. Cells were
then rinsed with PBS buffer at pH 7.4 and fixed in ice-cold
methanol for 10 min at −20 °C. After 45-min incubation in
10% FBS to block nonspecific protein binding, the fixed cells
were incubated with the following primary antibodies
anti-TRAF2 (sc-876) or anti-TRAF3 (sc-949) diluted
(1:300) in PBS containing 3 % low-fat milk at 37 °C for 2 h.
After washing with PBS containing 3 % low-fat milk, the
fixed cells were incubated with FITC-conjugated anti-IgG an-
tibody (1:150, Sigma-Aldrich) diluted in PBS containing 3 %
low-fat milk, at 37 °C for 1 h. After washing, the cover slips
were mounted on slides using Prolong Gold antifade reagent
(Invitrogen). Fluorescence microscopy was performed using a
Zeiss LSM510/UV confocal microscope with a ×63 oil im-
mersion objective. Immuno-labeled slides (n=4–5 represen-
tative fields per slide) were sectioned optically at 0.5-μm in-
tervals (one focal plane) through the cell monolayer to obtain
the appropriate focal depth. Images were captured and collect-
ed using Axiovision 4.7 program.
Statistical Analysis Otherwise noted in the figure legend,
data were presented as mean±SE from three independent ex-
periments. Statistical analysis was carried out with Student’s t
test for PCR data and with one-way ANOVA followed by
Tukey’s test for Luciferase data. p<0.05 was considered as
statistically significant difference.
Results
TRAF2 and TRAF3 Inducibly Translocate into the
Nucleus of Neurons and Neuro2a cells In order to determine
whether the TRAF proteins can inducibly translocate into the
nucleus, we first analyzed the subcompartmental localization
of TRAFs 1–7 in Neuro2a cells following CD40L stimulation.
It has previously been shown that both TRAFs 2 and 3 are
degraded following several hours of CD40L stimulation [24].
For this reason, we analyzed the subcompartmental localiza-
tion of the TRAFs following 5, 10, and 30 minutes of CD40L
stimulation (Fig. 1a). We found that each of the TRAFs is
variably present within the nucleus of Neuro2a cells. Also,
in concordance with our Western blot data, TRAF2 and
TRAF3 showed subnuclear localization in the form of puncta
as well as a diffuse presence in the cytoplasm (Fig. 1b).
Following CD40L stimulation, intranuclear protein levels of
TRAFs 4, 5, and 6 appeared to increase maximally by 5 min,
while TRAFs 2, 3, and 7 appear to increase maximally by
10 minutes, decreasing thereafter (Fig. 1a and Supplemental
Fig. 1). TRAF1was not induced to translocate into the nucleus
of Neuro2a cells by 30 min of CD40L stimulation. Since
TRAFs 2 and 3 had the most dramatic responses following
CD40L stimulation, and because they are the most commonly
studied TRAFs downstream of CD40 receptor signaling, we
focused the following experiments on TRAFs 2 and 3.
We next investigated the translocation of TRAFs 2, 3, and
p65/RelA in Neuro2a cells and mouse cortical neurons. We
again found that TRAFs 2 and 3 translocate to the nucleus
within 5 min of CD40L stimulation, peaking at 10 min, and
decreasing to basal levels by 30 min of stimulation (Fig. 2a).
This pattern of nuclear translocation differed from p65/RelA,
which did not increase within the nucleus until 30 min of
CD40L stimulation (Fig. 2a).
To determine whether our findings in Neuro2a cells were
retained in primary cells, we repeated these experiments in
mouse primary cortical neurons (Fig. 2b). We found that
TRAF2 translocated into the nucleus by 5 min of stimulation,
returning to basal levels by 30 minutes, while TRAF3 was




Fig. 1 Analysis of the nuclear localization and translocation of TRAFs
1–7 in Neuro2a cells following CD40L stimulation. a Western blot
analysis of the subcellular localization of TRAFs 1–7 in Neuro2a cells,
as well as the effect of CD40L stimulation on the subcellular localization
of TRAFs 1–7. Neuro2a cells were either untreated (control) or stimulated
for 5, 10, or 30 min with mouse CD40L (100 ng/mL), cytoplasmic and
nuclear extracts were then prepared, and a Western blot performed. As
controls for both the loading and the relative purity of the cytoplasmic and
nuclear extracts, Glut3 was used as a cytoplasmic marker, and RNA pol II
was used as a nuclear marker. b Confocal images of TRAF2 and TRAF3
in Neuro2a cells showing subnuclear puncta
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increased moderately following CD40L stimulation (Fig. 2b).
Moreover, p65/RelA accumulation in the nucleus following
CD40L stimulation was minimal (Fig. 2b). These data suggest
that TRAF2, TRAF3 and p65/RelA translocate to the nucleus
in CD40L stimulated Neuro2a cells and primary cortical
neurons.
We next analyzed whether CD40L induced nuclear trans-
location of TRAFs 2 and 3 in a noncentral nervous system cell
line, using pre-B lymphocytes (Daudi cells) as a model. Our
results in Daudi cells differed significantly from neuronal cell
types (Fig. 2c). Indeed, CD40L stimulation induced a strong
reduction in the levels of both TRAFs 2 and 3 in the nucleus
by 5 min, and these levels remained decreased at longer stim-
ulation time points. In contrast, CD40L stimulation strongly
induced the nuclear translocation of p65/RelA in these cells by
5 min, which remained increased by 30 min (Fig. 2c). These
results demonstrate that the translocation of TRAFs 2 and 3 in
response to CD40L stimulation functions in a cell-specific
manner and may be tissue-specific.
TRAF2 and TRAF3 Bind DNAWe next evaluated whether,
following nuclear translocation, TRAFs 2 and 3 were able to
bind to chromatin, and more specifically to the NF-kB pro-
moter element. For this purpose, we first prepared chromatin
extracts and analyzed chromatin binding by Western blotting.
We found that TRAF2 was minimally bound to chromatin,
while there appeared to be more TRAF3 bound, in
unstimulated Neuro2a cells (Fig. 3a). Surprisingly, CD40L
enhanced chromatin binding of both TRAFs 2 and 3 by
5 min of stimulation, reducing thereafter. These results show
for the first time that TRAFs 2 and 3 constitutively and
inducibly bind chromatin, suggesting that the TRAFs may
be direct regulators of transcriptional activity.
We next evaluated the possible binding of TRAFs 2
and 3 to the NF-kB consensus element by EMSA. NF-kB
DNA-binding activitywas constitutively present in unstimulated
Neuro2a nuclear extracts, in the form of four differentially
sized bands (Fig. 3b). The intensity of the upper three bands
progressively increased following 5, 10, and 30 min of
CD40L stimulation. However, preincubation of control and
10-min nuclear extract samples with antibodies to either
TRAFs 2 or 3 greatly attenuated DNA-binding activity.
These results suggest that TRAFs 2 and 3 constitutively
and inducibly bind to the NF-kB promoter element in a
time-dependent manner following CD40L stimulation.
Furthermore, both proteins are essential components of their
respective DNA-binding complexes because blocking their
interactions by antibody preincubation attenuated DNA-binding
activity.
To further demonstrate inducible binding of TRAFs 2 and 3
to the NF-kB promoter element, we conducted an NF-kB
promoter element oligoprecipitation assay. Similar to the
EMSA experiment, both TRAFs 2 and 3 bound to the
NF-kB consensus element in unstimulated extracts, with
TRAF3 bound to a greater degree than TRAF2 (Fig. 3c).
CD40L stimulation induced the binding of both TRAFs 2
Fig. 2 Analyses of the nuclear translocation of TRAF2, TRAF3, and
RelA in Neuro2a cells, cortical neurons, and Daudi cells. a Western
blot analysis of the effect of CD40L stimulation on the subcellular
localization of TRAFs 2 and 3 in Neuro2a cells. Neuro2a cells were
either untreated (control) or stimulated for 5, 10, or 30 min with mouse
CD40L (100 ng/mL), cytoplasmic and nuclear extracts were then
prepared, and a Western blot performed. As controls for both the
loading and the relative purity of the cytoplasmic and nuclear extracts,
HSP60 was used as a cytoplasmic marker, and Lamin A/C was used as a
nuclear marker. b Western blot analysis of the effect of CD40L
stimulation on the subcellular localization of TRAFs 2 and 3 in primary
cortical neurons. E15 mouse cortical neurons were either untreated
(control) or stimulated for 5, 10, or 30 minutes with mouse CD40L
(100 ng/mL), cytoplasmic and nuclear extracts were then prepared, and
a Western blot performed. As controls, Glut3 was used as a cytoplasmic
marker and HDAC1was used as a nuclear marker. cWestern blot analysis
of the effect of CD40L stimulation on the subcellular localization of
TRAFs 2 and 3 in Daudi cells. Daudi cells were either untreated
(control) or stimulated for 5, 10, or 30 min with human CD40L
(100 ng/mL), cytoplasmic and nuclear extracts were then prepared, and
a Western blot was performed. HSP60 and HDAC1 were used as
controls. C control
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and 3 to the NF-kB consensus element in a time-dependent
manner, with maximum binding after 30 min of stimulation.
In addition, p65/RelA inducibly bound to the NF-kB consen-
sus element following 30 min of CD40L stimulation, in
direct correlation to the increased levels of p65RelA in
CD40L-stimulated nuclear extracts (Fig. 2b). Collectively,
these results support our EMSA analyses and show that
TRAFs 2 and 3 both constitutively and inducibly bind to the
NF-kB promoter element and form part of a transcriptional
complex containing TRAFs 2 and 3 along with p65/RelA.
Considering the differences between the nuclear transloca-
tion of TRAFs 2 and 3 between Neuro2a and Daudi cells, we
next analyzed the chromatin binding of these proteins in
Daudi cells. The levels of TRAFs 2 and 3 binding to chroma-
tin correlated with their nuclear levels (compare Fig. 3d to
Fig. 2c). Particularly, both TRAFs 2 and 3 were constitutively
bound to chromatin at high levels, and this binding greatly
diminished following CD40L stimulation. These results fur-
ther show that the translocation and chromatin binding of
TRAFs 2 and 3 may function in a cell-specific manner, but
also suggest that the TRAFs may have a role in regulating
transcriptional activity in Daudi cells as well.
TRAFs Differentially Function as Coactivators and/or
Corepressors of Transcription Previous studies have indi-
cated that overexpression of TRAFs 2 and 6 can induce
NF-kB transcriptional activity [16, 22, 26, 27]. Since we dem-
onstrated that TRAFs 2 and 3 bind to chromatin, we next ana-
lyzed whether the TRAF proteins could activate transcription
using a luciferase assay reporter system (Fig. 4). As previously
shown, we demonstrated that overexpressing TRAF2 induces
NF-kB transcriptional activity in Neuro2a (2.7-fold) and HEK
293 cells (2.2-fold) (Fig. 4a) [14]. In consideration of the
previous findings that TRAF2 functions as an E3-ubiquitin
ligase via the RING finger domain, and that deletion of the
RING finger can attenuate its ability to induce transcriptional
activity [9, 10, 22], we repeated the overexpression experi-
ment using a deletion construct lacking the RING finger do-
main, ΔN-TRAF2. We found that deletion of the RING fin-
ger domain reduces TRAF2 induced NF-kB transcriptional
activity.
In order to determine the direct transactivation potential of
TRAF2, we next analyzed the transcriptional activity induced
by TRAF2 coexpressed with a 5x Gal4 promoter-driven lucif-
erase reporter plasmid (Fig. 4b). As a result, overexpression of
Fig. 3 Inducible binding of TRAF2 and TRAF3 to chromatin and the
NF-kB consensus element. a Western blot analysis of the binding of
TRAFs 2 and 3 to chromatin in Neuro2a cells, following CD40L
stimulation. Neuro2a cells were either untreated (control) or stimulated
for 5, 10, or 30 min with mouse CD40L (100 ng/mL), chromatin extracts
were then prepared, and a Western blot was performed. Histone H3 was
used as a loading control and remained constant in all four conditions. b
EMSA analysis of NF-kB DNA-binding activity in Neuro2a extracts
following CD40L stimulation, and the effect of TRAF 2 or 3 antibody
preincubation on such activity. Neuro2a cells were either untreated
(control) or stimulated for 5, 10, or 30 min with mouse CD40L
(100 ng/mL), nuclear extracts were then prepared, and an EMSA was
performed. The extracts (5 μg) were then either untreated or
preincubated with antibody to TRAF 2 or 3, or with 100-fold excess of
unlabeled NF-kB or NFAT consensus elements, as controls for the
specificity of the NF-kB DNA-binding complexes. Incubation with a
100-fold excess of unlabelled NF-kB promoter element greatly
attenuated the DNA-binding of all four bands, while incubation with an
excess of unlabeled NFATelement had no effect on any of the four bands,
demonstrating that all four bands were specific. c Western blot
analysis of the binding of TRAF2, TRAF3, and RelA to the NF-kB
consensus element following NF-kB oligoprecipitation performed on
CD40L-stimulated Neuro2a nuclear extracts. Neuro2a cells were either
untreated (control) or stimulated for 5, 10, or 30 min with mouse
CD40L (100 ng/mL), and nuclear extracts were prepared. The extracts
(100 μg) were then incubated overnight with NF-kB-cross-linked agarose
beads in DNA-binding buffer. The following day, the beads were
precipitated and washed and a Western blot was performed. d Western
blot analysis of the binding of TRAFs 2 and 3 to chromatin in Daudi cells,
following CD40L stimulation. Daudi cells were either untreated (control)
or stimulated for 5, 10, or 30 min with human CD40L (100 ng/mL),
chromatin extracts were then prepared, and a Western blot was
performed. Histone H3 was used as a loading control. C control, T2
TRAF2, T3 TRAF3, Ab antibody
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TRAF2 induced a 14.6-fold increase in luciferase activity in
Neuro2a cells, and a 7.2-fold increase in HEK 293 cells. In
this experiment, deletion of the RING finger domain
completely abolished the transactivation potential of TRAF2
in both Neuro2a and HEK 293 cells. These results suggest that
TRAF2 can function directly as a transcription factor.
Based on the finding that TRAF2 functions as a direct
transcriptional activator, we further explored the possibility
that the TRAFs could function as coactivators or corepressors.
In order to determine the coactivation/corepression potential
of the TRAFs, we coexpressed Gal4-tagged isoforms of
TRAF1-7 along with a 4x Gal4-minimal TK promoter-driven
luciferase reporter plasmid. This reporter plasmid maintains
a basal level of transcriptional activity, allowing for the
analysis of transcriptional repression [28]. We found that
each of the TRAFs functioned as a coactivator or core-
pressor for the minimal TK promoter activity in both Neuro2a
and HEK 293 cells, with the exception of TRAFs 4 and 5,
which had no effect in either cell type (Fig. 4c). In Neuro2a cells,
TRAFs 2, 6, and 7 were found to coactivate the minimal
Fig. 4 Transcriptional regulatory potentials of TRAFs 1–7. a NF-kB
dual-luciferase assay performed on Neuro2a (light gray) and HEK 293
(dark gray) cell extracts , with the overexpression the pBind vector,
pBind-TRAF2, or pBind-ΔN-TRAF2. Neuro2a and HEK 293 cells
were transfected either with the control pBind vector or with
pBind-TRAF2 or pBind-ΔN-TRAF2 (1 μg each). After 24 h, the cells were
lysed and dual-luciferase assays were performed. b 5x Gal4 promoter-driven
dual-luciferase assay performed on Neuro2a and HEK 293 cell
extracts, with the overexpression of the pBind vector, pBind-TRAF2, or
pBind-ΔN-TRAF2. c 4x Gal4-minimal TK promoter-driven dual-luciferase
assay performed on Neuro2a and HEK 293 cell extracts, with
the overexpression of the pBind vector or pBind-TRAF1-7. d 4x
Gal4-minimal TK promoter-driven dual-luciferase assay performed on
Neuro2a and HEK 293 cell extracts, with the overexpression of the
pBind vector, pBind-TRAF2, or pBind-ΔN-TRAF2. e 5x Gal4
promoter-driven dual-luciferase assay performed on Neuro2a and HEK
293 extracts, with the overexpression of the pBind vector or pBind-RelA,
in turn with either the pCMV-Tag2C vector or pCMV-Tag2B-TRAF1-7. f
5x Gal4 promoter-driven dual-luciferase assay performed on Neuro2a
and HEK 293 cell extracts overexpressed with pBind RelA, in turn
coexpressed with the pCMV-Tag2B vector, pCMV-Tag2B-TRAF2 or
pCMV-Tag2B-ΔN-TRAF2. Each of these experiments was repeated at
least three times, and the data represent the mean of at least four
independent sample readings from one representative experiment ± the
SEM, normalized to the pBind Renilla luciferase control readings. One-way
ANOVA was performed, followed by Tukey’s test; *≤0.05; **≤0.001.
VC vector control, T1 TRAF1, T2 TRAF2, T3 TRAF3, T4 TRAF4,
T5 TRAF5, T6 TRAF6, T7 TRAF7
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TK promoter activity, while TRAFs 1 and 3 were found to
corepress it. In HEK 293 cells, TRAFs 1, 2, 3, 6, and 7 all had
a coactivator function. Surprisingly, while the majority of the
TRAF proteins maintained similar coactivation or
corepression patterns between both Neuro2a and HEK 293
cells, TRAFs 1 and 3 had very different functions between
the two cell types, again suggesting that particular TRAF pro-
teins may have cell-specific functions. In order to determine
the role of the RING finger domain in the coactivation activity
of TRAF2 in both Neuro2a and HEK 293 cells, we next re-
peated the experiment with the ΔN-TRAF2 construct, and
found that deletion of the RING finger domain abolished the
coactivation potential of TRAF2 in both cell types (Fig. 4d).
Since the TRAFs can function as coactivators and core-
pressors, we next evaluated whether coexpression of the
TRAFs could have an effect on coactivating or corepressing
Gal4-tagged RelA-induced transcriptional activity (Fig. 4e).
In Neuro2a cells, TRAFs 2, 6, and 7 enhanced, while
TRAFs 1, 4, and 5 repressed RelA-induced, transcriptional
activity. In HEK 293 cells, TRAFs 1, 2, 4, 5, 6, and 7 all
repressed RelA-induced transcriptional activity. In both cell
types, TRAF3 had no effect on RelA-induced transcriptional
activity. Additionally, deletion of the RING finger domain
from TRAF2 attenuated the coactivation or corepression ac-
tivity of TRAF2 for RelA-induced transcriptional activity in
Neuro2a and HEK 293 cells, respectively (Fig. 4f). Taken
together, these results show that the TRAF proteins can
function as coactivators or corepressors of a known tran-
scription factor, RelA, dependent upon the cell type, and
that their coactivation or corepression potential may be due
in part to the E3 ubiquitin-ligase activity of their RING
finger domains.
CD40L Induces a Transcriptional Complex Consisting of
pRNA PolII, TRAF2, TRAF3, and p65 in Neuro2a Cells
Based upon the data described above, we wanted to determine
if CD40L could stimulate TRAF2 and or TRAF3 binding to
an NF-kB-dependent promoter, in vivo. To investigate this,
we performed ChIP-qPCR analysis of the Icam-1 promoter
in Neuro2A cells. Expression of Icam-1 was shown to be
rapidly induced upon CD40L activation [3, 4, 29, 30]. A dia-
gram of the Icam-1 promoter is shown if Fig. 5a.
In these experiments, Neuro2A cells were treated with me-
dia or CD40L for 5–30 min and ChIP-qPCR analysis was
performed. Our data demonstrates that TRAF2 and phospho-
RNA Polymerase II (pRNA PoIII) are recruited to the NF-kB
consensus element within 5 min of CD40L stimulation, prior
to either p65/RELA or TRAF3 promoter occupancy (Fig. 5b).
Significant binding of p65/RelA and TRAF3 is further ob-
served at 10 and 30 min poststimulation, respectively
(Fig. 5b). Maximal binding of TRAF2, pRNA PoIII, p65/
RelA, and TRAF3 occurred at 30 min of CD40L stimulation.
TRAF2 Containing Complexes Are Critical for H2B-
Ubiquitination at the Icam-1 Promoter and Regulate
Icam-1 Gene Expression Since TRAF2 recruitment to the
Icam-1 promoter was an initial event preceding recruitment
of other complex members, we investigated TRAF2’s effects
on histone H2B Lys120 mono-ubiquitination (H2Bub), a
posttranslational modification associated with the facilitation
of transcription initiation and elongation [31]. ChIP experi-
ments revealed a significant increase in H2Bub levels upon
10 min of CD40L stimulation in Neuro2A cells (Fig. 5c). The
increased occupancy by H2Bub was specific for the NF-kB
consensus site, as compared to the control region of the Icam-
1 gene promoter. On the other hand, an early transcription
repressive epigenetic modification as in ubiquitination of his-
tone H2Awas probed and no significant difference in H2Aub
occupancy was seen after 10 min of CD40L treatment
(Supplemental Fig. 3A). Next, we show that siRNA knock-
down of TRAF2 significantly inhibited recruitment of
TRAF2, p65, pRNAPolII to the promoter and H2Bub and
(Fig. 5b, c). Finally, we demonstrate that knocking down
TRAF2 and p65 significantly inhibits Icam-1 gene transcrip-
tion following CD40L stimulation. Interestingly, inhibition of
TRAF2 significantly repressed Icam-1 mRNA generation as
early as 5 min and for up to 30 min whereas inhibiting p65
attenuated Icam-1 expression only at 30 min of stimulation
(Fig. 5d). As a control, we demonstrate knockdown of
TRAF2 and p65 mRNAs by their specific siRNAs
(Supplemental Fig. 3B and C).
Discussion
In this study, we demonstrated, for the first time, that the
TRAFs are variably present within the nucleus of Neuro2a
cells and primary cortical neurons and that TRAFs 2 and 3
rapidly translocate into the nucleus following treatment with
CD40L. Our in vitro studies have shown that both TRAFs 2
and 3 bind to chromatin and the NF-kB promoter element and
can function as coactivators or corepressors of transcriptional
activity. Additionally, TRAF2 can directly induce transcrip-
tional activity, albeit weakly in comparison to typical tran-
scription factors. We find these results extremely interesting
for a number of reasons, including how rapidly the TRAFs
translocate into the nucleus and associate with chromatin, that
they have the capacity to function as transcriptional regulators
and that theymay have different functions and responses with-
in different cell types or evenwith different target transcription
factors within the same cell. In support of our in vitro data, we
determined using ChIP-qPCR analysis that TRAFs 2 and 3
form part of an active transcriptional complex at the Icam-1
promoter and that TRAF2 is required for p65 and pRNAPolII
binding. We further demonstrate that a complex containing
TRAF2 ubiquitinates H2b. These findings demonstrate a
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Fig. 5 TRAF2 regulates mouse Icam-1 gene expression upon CD40L
stimulation in Neuro2a cells. a Schematic diagram of mouse Icam-1 gene
promoter. b Time course of TRAF2, pRNAPolII, and p65 recruitment to
mouse icam-1 promoter upon CD40L treatment in Neuro2a cells. qPCR
analysis of TRAF2, p65, TRAF3, and pRNAPolII chromatin immuno-
precipitation (ChIP) after 5, 10, and 30 min of CD40L (100 ng/mL)
treatment. ChIP qPCR analysis shows significant increase in TRAF2
and pRNAPolII recruitment to p65 consensus sequence (p65 C S) starting
5 min after CD40L treatment. At 10 min, p65 joined TRAF2 and
pRNAPolII at the promoter. Following 30 min, TRAF3 joined the
complex and maximal levels of TRAF2, pRNAPolII and p65 occurred
at this time. Knockdown of TRAF2 by SiRNA (SiTRAF2) abrogated
p65, and pRNAPolII to the complex on the Icam-1 promoter. The
TRAF3 recruitment to the promoter was not investigated since it did
not show any changes in levels at the tested 10-min time point.
Nonspecific IgG was used as an internal control while primers flanking
an irrelevant control sequence were used as external controls. c
Monoubiquitination of H2B and TRAF2 recruitment to the Icam-1 gene
promoter. Left panel: qPCR analysis of TRAF2 ChIP after 10 min of
CD40L (100 ng/mL) treatment show 3.7-fold increase in TRAF2
recruitment to p65 consensus sequence (p65 C S) as compared to
nontreated cells. This increase is abrogated when TRAF2 was knocked
down using SiRNA. Right panel: qPCR analysis of H2B-Ub (Lys 120)
ChIP after 10 min of CD40L (100 ng/mL) treatment show 29.8-fold
increase in H2B monoubiquitination at the p65 consensus sequence
(p65 C S) as compared to nontreated cells. This increase is abrogated
when TRAF2 was knocked down using SiRNA. Nonspecific IgG was
used as an internal control while primers flanking an irrelevant control
sequence were used as external controls. d Mouse Icam-1 mRNA
expression levels upon CD40L treatment in Neuro2a cells. qPCR
analysis of Icam-1 mRNA expression in Neuro2a cells treated with
Scrambled, TRAF2, and p65 SiRNA at 0, 5, 10, and 30 min after
CD40L (100 ng/mL) treatment. TRAF2 knockdown shows dramatic
decrease in Icam-1 mRNA expression starting 5 min while p65
knockdown significantly affects Icam-1 expression at the 30-min time
point. TSS transcriptional start site. Ctrl irrelevant control sequence, F
and R forward and reverse primers, respectively. *p< 0.05
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novel function for the TRAFs in the nucleus, as the TRAFs
have been previously considered to function exclusively with-
in the cytoplasm either as adaptor proteins and or as
E3-ubiquitin ligases.
Interestingly, an ever increasing number of ubiquitin li-
gases have been found to function within the nucleus [32].
These proteins can function as coactivators or corepressors,
regulating transcription factors either by enhancing their acti-
vation or inducing their degradation or processing [33, 34]. In
this case, it is very possible that the TRAFs may function to
regulate transcriptional activity in a similar manner, as their
rapid regulation of transcriptional activation could have a
wide-ranging, direct regulatory effect that would explain the
number of pathways and functions that the various TRAFs
have been found to regulate. Additionally, since both
TRAFs 2 and 6 have been found to catalyze Lys-63-linked
polyubiquitination [35, 36], this suggests that the TRAFs may
also directly activate proteins, rather than solely signal pro-
teins for degradation or proteasomal processing. However, in
several cases, the transcriptional regulatory capacity of
TRAF2 was not entirely abolished by deletion of the RING
finger, and TRAF1 has the capacity to function as a corepres-
sor without having a RING finger domain. Therefore, this
suggests that additional domains must have transcriptional
regulatory capacity and will require additional research in or-
der to parse out such functions.
Considering that several of the TRAFs were found to have
different transcriptional activities between Neuro2a and HEK
293 cells, it is possible that the individual TRAFs do not have a
specific coactivator or corepressor potential. In fact, as some of
the TRAFs have a coactivator activity in one cell type and a
corepressor activity in another cell type (namely TRAFs 1 and
3 as coactivators in HEK 293 cells and corepressors in Neuro2a
cells), it is possible that the functions of the various TRAFsmay
depend on the intracellular milieu, as defined by the proteins
and cofactors that are individually present within the different
cell types, the stimulus that activates them, and the specific
target protein(s) that they are regulating. Indeed, TRAF2 func-
tions as a coactivator for the minimal TK promoter activity in
HEK 293 cells, but as a corepressor for RelA-induced activity
in the same cell type. Additionally, neither TRAF4 nor TRAF5
function as a coactivator or corepressor of the minimal TK
promoter activity in either Neuro2a or HEK 293 cells, while
both function as corepressors for RelA-induced transcriptional
activity in both cell types. Finally, a clearer example of this is
the finding that TRAF3 functions as corepressor of the minimal
TK promoter activity in Neuro2a cells, and as a coactivator in
HEK 293 cells, without having any effect on RelA-induced
transcriptional activity in either cell type.
Another interesting finding is that TRAFs 2 and 3 translo-
cate into the nucleus of Neuro2a cells and primary cortical
neurons following CD40L stimulation, while in Daudi cells,
they rapidly exit the nucleus or are quickly degraded. This
suggests further differences in the mechanisms of TRAF sig-
naling between cell types, in addition to the differences in tran-
scriptional regulatory potentials. We cannot exclude, however,
that in Daudi cells, other TRAFs may translocate into the nu-
cleus following CD40L stimulation, or that stimulation with
cytokines other than CD40L may have other effects. Indeed,
nuclear extracts from unstimulated Daudi cells had high con-
stitutive levels of both TRAFs 2 and 3, and both were consti-
tutively bound to chromatin, suggesting that both proteins may
have a function within the nucleus of Daudi cells, as well.
Overall, our data show for the first time that the TRAF
proteins can translocate into the nucleus, bind to both chromatin
and the NF-kB consensus element. Additionally, we show that
TRAF2 and TRAF3 are components of DNA-binding com-
plexes containing p65 and pRNA PolII, and that this complex
epigenetically modifies H2b at the Icam-1 promoter (Fig. 6).
This is very intriguing because it suggests that inducible tran-
scriptional complexes containing different TRAF proteins form
at the Icam-1, and possibly other promoters in a temporal spe-
cific pattern. Our data also demonstrates that TRAF2 partici-
pates in the orchestration of histone H2 ubiquitination, which
contributes to the selective regulation of NF-kB-dependent
genes. Finally, our observation of TRAF3 binding to chromatin
at 5 min post-CD40L stimulation (Fig. 4a), but not at the Icam-1
promoter at this time point (Fig. 5b) suggests that the temporal
occupancy and the composition of the TRAF transcriptional
complexes is context dependent.
Overall, these findings are important given the diverse
functions that continue to be attributed to the wide range of
receptor families (e.g., TNFR, TLR, and NLR) that utilize the
TRAFs to orchestrate signaling. Future research into the genes
that are regulated by the specific TRAF complexes will further
elucidate how the TRAFs regulate signaling, as well as












Fig. 6 Model schema describing novel transcriptional capabilities of
TRAFs 2 and 3 in neurons. TRAFs 2/3, p65, and pRNAPolII form part
of a transcriptional complex on Icam-1 gene promoter upon CD40L
stimulation. TRAF2 recruitment to the nucleus is critical for the
monoubiquitination of H2B, a transcription permissive epigenetic
modification
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whether dysfunctions in TRAF signaling may be associated
with known disorders. If specific TRAF complexes are found
to regulate specific genes, then pharmacological targeting of
individual TRAF complexes may allow for the highly specific
inhibition of signaling events downstream of these receptors,
without compromising overall receptor signaling, transcrip-
tion factor pathways, or cellular systems.
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